

Ipsogen announces the success of a €2.5 million reserved capital increase

Marseille, June 15th 2009 - **IPSOGEN** (Alternext - FR0010626028 - ALIPS), a cancer 'profiler' that develops, manufactures and markets molecular diagnostic tests for leukemia and breast cancer, today announces that it has successfully carried out a €2.5 million capital increase.

This raising of funds was decided opportunistically, within the framework of the law that reduces wealth tax (TEPA act). It took place via a reserved capital increase in accordance with the decisions approved during the company's Annual General Meeting on May 20 2009. This capital increase concerned a total of 367,647 shares issued at €6.80 per share.

Stanislas PIOT, CFO of IPSOGEN, comments: *"This raising of a further 2.5 million euros was essentially carried out with new investors. Done at a similar price to the one at the time of the IPO in June 2008, it reflects investors' confidence in our strategy and in our share price's upside potential."*

Vincent FERT, CEO of IPSOGEN, adds:

"with such a strong balance sheet the company may take advantage of new opportunities and accelerate its development which was already assured by our very satisfactory level of cash before this capital increase."

For 2009, IPSOGEN anticipates similar sales growth to that recorded in 2008.

About IPSOGEN

Ipsogen, Cancer Profiler, develops and markets molecular diagnostic tests designed to map diseases in order to guide patients and oncologists decisions along their complex therapeutic path.

With more than 70 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. Its initial goal will be to provide diagnostic information that remained unavailable until now.

Strengthened by its first-rate scientific, clinical and technological partnerships, in addition to its highly-skilled multidisciplinary team in France and the USA, Ipsogen is striving to become the leader in the molecular profiling of cancers. It is pursuing its development and promotion of diagnostic standards that have a significant impact on patients, medical professionals and society. Ipsogen employed 51 people as of March 31, 2009. Its headquarters are located in Marseille, France.

The company has also a subsidiary, Ipsogen Inc., in New Haven, CT, USA.

For more information, visit: www.ipsogen.com

Contacts



IPSOGEN

Vincent Fert
President and CEO
Tél : + 33 (0)4 9129 3090
fert@ipsogen.com

Stanislas Piot
CFO
Tél : + 33 (0)4 9129 3090
piot@ipsogen.com

NewCap

**Communication financière et
relations investisseurs**

Axelle Vuillermet & Pierre
Laurent
Tél : + 33 (0)1 44 71 94 93

ipsogen@newcap.fr